Mary Szela

Mary Szela has more than 32 years of experience as an executive in the biotechnology and pharmaceutical industry, serving on the board of directors of publicly held companies Receptos Inc., Novo Nordisk, Novelion Therapeutics, Coherus Biosciences and Alimera Sciences. Ms. Szela currently serves on the boards of Kura Oncology, Senda Biosciences and TriSalus Life Sciences. Prior to joining TriSalus, Ms. Szela was Chief Executive Officer of Novelion Therapeutics, where she resolved the significant legal, regulatory and compliance issues facing the company and executed a merger to recapitalize the company within the first year.

Ms. Szela earned a B.S. in Nursing and an MBA from the University of Illinois at Chicago.